MedTrace Logo

Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Repeated Dose Transdermal Rotigotine in Japanese and Caucasian Subjects

NCT01854216 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2014-10-20

No results posted yet for this study

Summary

To investigate the repeated dose Pharmacokinetics (PK) of transdermally delivered Rotigotine in Japanese and Caucasian female and male healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

Rotigotine transdermal patch 1mg / 24 hours

Rotigotine transdermal patch, repeated dose application over 24 hours; 1 mg / 24 hours

DRUG

Rotigotine transdermal patch 2 mg / 24 hours

Rotigotine transdermal patch, repeated dose application over 24 hours; 2 mg / 24 hours

DRUG

Rotigotine transdermal patch 4 mg / 24 hours

Rotigotine transdermal patch, repeated dose application over 24 hours; 4 mg / 24 hours

Sponsors & Collaborators

  • UCB BIOSCIENCES GmbH

    lead INDUSTRY

Principal Investigators

  • UCB Clinical Trial Call Center · +1 877 822 9493 (UCB)

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-12-31
Primary Completion
2003-03-31
Completion
2003-03-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01854216 on ClinicalTrials.gov